Description: This presentation addresses a novel pharmaceutical excipient awaiting first-in-human trials, primarily for injections: hyaluronic acid nanogel. The hyaluronic acid nanogel is a nano-sized hydrogel particle (20-100 nm) that can load various APIs, including peptides or proteins, simply and easily by mixing with them. It acts as an API carrier, facilitating the subcutaneous sustained release of APIs, including long-acting peptides, through in-situ depot formation and enhancing the solubility of poorly water-soluble APIs, including cyclic peptides.
Learning Objectives:
Upon completion, participants will understand a cutting-edge approach using a novel pharmaceutical excipient to modulate the release profiles of biologics, especially peptides, and learn about an in vitro release model to comprehend the pharmacokinetic profile and the API release mechanism.
Upon completion, participants will learn about a novel solubilizer that dramatically enhances the solubility of poorly water-soluble APIs, including cyclic peptides, and understand its effect on their pharmacokinetic profile.
Upon completion, participants will gain insight into the significance of the hyaluronic acid nanogel compared to already-known excipients such as PLGA microparticles or polysorbate 80.
.png)
